C
Changting Xiao
Researcher at University of Toronto
Publications - 71
Citations - 2953
Changting Xiao is an academic researcher from University of Toronto. The author has contributed to research in topics: Chylomicron & Insulin resistance. The author has an hindex of 29, co-authored 64 publications receiving 2504 citations. Previous affiliations of Changting Xiao include University of Saskatchewan & University of Guelph.
Papers
More filters
Journal ArticleDOI
Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies
TL;DR: Lipotoxicity is likely to be one contributor to the complex array of genetic and metabolic insults that result in the relentless decline in pancreatic β-cell function in those destined to develop type 2 diabetes, and mechanisms involved in this lipotoxicity are promising therapeutic targets.
Journal ArticleDOI
Sodium Phenylbutyrate, a Drug With Known Capacity to Reduce Endoplasmic Reticulum Stress, Partially Alleviates Lipid-Induced Insulin Resistance and β-Cell Dysfunction in Humans
TL;DR: It is suggested that PBA may provide benefits in humans by ameliorating the insulin resistance and β-cell dysfunction induced by prolonged elevation of free fatty acids.
Journal ArticleDOI
Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol.
TL;DR: It is postulate that targeting the central abnormality of the atherogenic dyslipidemia complex, the elevation of triglyceride-rich lipoprotein particles, represents a new frontier in CVD prevention and is likely to prove the most effective strategy in correcting most aspects of the atheism complex, thereby preventing CVD events.
Journal ArticleDOI
Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans.
TL;DR: Oral ingestion of fats with differing degrees of saturation resulted in different effects on insulin secretion and action, and failure of insulin secretion to compensate for insulin resistance implies impaired beta cell function in the SFA study.
Journal ArticleDOI
Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
TL;DR: These results suggest a possible direct effect of exenatide on intestinal lipoprotein particle production, independent of changes in weight gain and satiety as seen in long-term studies and independent ofChanges in gastric emptying.